Toll-like receptors as potential therapeutic targets in cardiac dysfunction

Bibliography

• Anderson KV, Jurgens G, Nusslein-Volhard C. Establishment of dorsal-ventral polarity in the Drosophila embryo: genetic studies on the role of the Toll gene product. Cell 1985;42:779-89
   PubMed Web of Science ®Google Scholar
• Lemaitre B, Nicolas E, Michaut L, The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 1996;86:973-83
   PubMed Web of Science ®Google Scholar
• Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997;388:394-7
   PubMed Web of Science ®Google Scholar
• Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006;124:783-801
   PubMed Web of Science ®Google Scholar
• Frantz S, Ertl G, Bauersachs J. Mechanisms of disease: Toll-like receptors in cardiovascular disease. Nat Clin Pract Cardiovasc Med 2007;4:444-54
   PubMedGoogle Scholar
• Boyd JH, Mathur S, Wang Y, Toll-like receptor stimulation in cardiomyoctes decreases contractility and initiates an NF-kappaB dependent inflammatory response. Cardiovasc Res 2006;72:384-93
   PubMed Web of Science ®Google Scholar
• Frantz S, Kobzik L, Kim YD, Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium. J Clin Invest 1999;104:271-80
   PubMed Web of Science ®Google Scholar
• Ohashi K, Burkart V, Flohe S, Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J Immunol 2000;164:558-61
   PubMed Web of Science ®Google Scholar
• Vabulas RM, Ahmad-Nejad P, da Costa C, Endocytosed HSP60s use toll-like receptor 2 (TLR2) and TLR4 to activate the toll/interleukin-1 receptor signaling pathway in innate immune cells. J Biol Chem 2001;276:31332-9
   PubMed Web of Science ®Google Scholar
• Legare JF, Oxner A, Heimrath O, Heat shock treatment results in increased recruitment of labeled PMN following myocardial infarction. Am J Physiol Heart Circ Physiol 2007;293:H3210-15
   Web of Science ®Google Scholar
• Kim SC, Stice JP, Chen L, Extracellular heat shock protein 60, cardiac myocytes, and apoptosis. Circ Res 2009;105:1186-95
   PubMed Web of Science ®Google Scholar
• Currie RW. Effects of ischemia and perfusion temperature on the synthesis of stress-induced (heat shock) proteins in isolated and perfused rat hearts. J Mol Cell Cardiol 1987;19:795-808
   PubMed Web of Science ®Google Scholar
• Knowlton AA, Kapadia S, Torre-Amione G, Differential expression of heat shock proteins in normal and failing human hearts. J Mol Cell Cardiol 1998;30:811-18
   PubMed Web of Science ®Google Scholar
• Tanonaka K, Yoshida H, Toga W, Myocardial heat shock proteins during the development of heart failure. Biochem Biophys Res Commun 2001;283:520-5
   PubMed Web of Science ®Google Scholar
• Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002;418:191-5
   PubMed Web of Science ®Google Scholar
• Bonaldi T, Talamo F, Scaffidi P, Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J 2003;22:5551-60
   PubMed Web of Science ®Google Scholar
• Park JS, Svetkauskaite D, He Q, Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 2004;279:7370-7
   PubMed Web of Science ®Google Scholar
• Tian J, Avalos AM, Mao SY, Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 2007;8:487-96
   PubMed Web of Science ®Google Scholar
• Kohno T, Anzai T, Naito K, Role of high-mobility group box 1 protein in post-infarction healing process and left ventricular remodelling. Cardiovasc Res 2009;81:565-73
   PubMed Web of Science ®Google Scholar
• Kitahara T, Takeishi Y, Harada M, High-mobility group box 1 restores cardiac function after myocardial infarction in transgenic mice. Cardiovasc Res 2008;80:40-6
   PubMed Web of Science ®Google Scholar
• Takahashi K, Fukushima S, Yamahara K, Modulated inflammation by injection of high-mobility group box 1 recovers post-infarction chronically failing heart. Circulation 2008;118:S106-14
   PubMed Web of Science ®Google Scholar
• Okamura Y, Watari M, Jerud ES, The extra domain A of fibronectin activates Toll-like receptor 4. J Biol Chem 2001;276:10229-33
   PubMed Web of Science ®Google Scholar
• Scheibner KA, Lutz MA, Boodoo S, Hyaluronan fragments act as an endogenous danger signal by engaging TLR2. J Immunol 2006;177:1272-81
   PubMed Web of Science ®Google Scholar
• Leadbetter EA, Rifkin IR, Hohlbaum AM, Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 2002;416:603-7
   PubMed Web of Science ®Google Scholar
• Fischer M, Ehlers M. Toll-like receptors in autoimmunity. Ann NY Acad Sci 2008;1143:21-34
   PubMed Web of Science ®Google Scholar
• Zhang P, Cox CJ, Alvarez KM, Cutting edge: cardiac myosin activates innate immune responses through TLRs. J Immunol 2009;183:27-31
   PubMed Web of Science ®Google Scholar
• Cunningham MW, Antone SM, Gulizia JM, Cytotoxic and viral neutralizing antibodies crossreact with streptococcal M protein, enteroviruses, and human cardiac myosin. Proc Natl Acad Sci USA 1992;89:1320-4
   PubMed Web of Science ®Google Scholar
• Michelsen KS, Arditi M. Toll-like receptor signaling and atherosclerosis. Curr Opin Hematol 2006;13:163-8
   PubMed Web of Science ®Google Scholar
• Arslan F, Smeets MB, O'Neill LA, Myocardial ischemia/reperfusion injury is mediated by leukocytic toll-like receptor-2 and reduced by systemic administration of a novel anti-toll-like receptor-2 antibody. Circulation 2010;121:80-90
   PubMed Web of Science ®Google Scholar
• Frantz S, Bauersachs J, Kelly RA. Innate immunity and the heart. Curr Pharm Des 2005;11:1279-90
   PubMed Web of Science ®Google Scholar
• Frantz S, Ertl G, Bauersachs J. Toll-like receptor signaling in the ischemic heart. Front Biosci 2008;13:5772-9
   PubMed Web of Science ®Google Scholar
• Frantz S, Bauersachs J, Ertl G. Post-infarct remodelling: contribution of wound healing and inflammation. Cardiovasc Res 2009;81:474-81
   PubMed Web of Science ®Google Scholar
• Ueland T, Espevik T, Kjekshus J, Mannose binding lectin and soluble Toll-like receptor 2 in heart failure following acute myocardial infarction. J Card Fail 2006;12:659-63
   PubMed Web of Science ®Google Scholar
• Ertl G, Frantz S. Wound model of myocardial infarction. Am J Physiol Heart Circ Physiol 2005;288:H981-3
   Web of Science ®Google Scholar
• Ertl G, Frantz S. Healing after myocardial infarction. Cardiovasc Res 2005;66:22-32
   PubMed Web of Science ®Google Scholar
• Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004;4:499-511
   PubMed Web of Science ®Google Scholar
• Muzio M, Polentarutti N, Bosisio D, Toll-like receptor family and signalling pathway. Biochem Soc Trans 2000;28:563-6
   PubMed Web of Science ®Google Scholar
• Verstak B, Hertzog P, Mansell A. Toll-like receptor signalling and the clinical benefits that lie within. Inflamm Res 2007;56:1-10
   PubMed Web of Science ®Google Scholar
• Coll RC, O'Neill LA. New insights into the regulation of signalling by toll-like receptors and nod-like receptors. J Innate Immun 2010;2:406-21
   PubMed Web of Science ®Google Scholar
• Kumar H, Kawai T, Akira S. Toll-like receptors and innate immunity. Biochem Biophys Res Commun 2009;388:621-5
   PubMed Web of Science ®Google Scholar
• Arbour NC, Lorenz E, Schutte BC, TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 2000;25:187-91
   PubMed Web of Science ®Google Scholar
• Zee RY, Hegener HH, Gould J, Toll-like receptor 4 Asp299Gly gene polymorphism and risk of atherothrombosis. Stroke 2005;36:154-7
   PubMed Web of Science ®Google Scholar
• Edfeldt K, Bennet AM, Eriksson P, Association of hypo-responsive toll-like receptor 4 variants with risk of myocardial infarction. Eur Heart J 2004;25:1447-53
   PubMed Web of Science ®Google Scholar
• Ameziane N, Beillat T, Verpillat P, Association of the Toll-like receptor 4 gene Asp299Gly polymorphism with acute coronary events. Arterioscler Thromb Vasc Biol 2003;23:e61-4
   PubMed Web of Science ®Google Scholar
• Meng X, Ao L, Brown JM, LPS induces late cardiac functional protection against ischemia independent of cardiac and circulating TNF-alpha. Am J Physiol 1997;273:H1894-902
   Google Scholar
• Lipton BP, Bautista AP, Delcarpio JB, Effects of endotoxin on neutrophil-mediated I/R injury in isolated perfused rat hearts. Am J Physiol Heart Circ Physiol 2001;280:H802-11
   Web of Science ®Google Scholar
• Mazenot C, Gobeil F, Ribuot C, Delayed myocardial protection induced by endotoxin does not involve kinin B1-receptors. Br J Pharmacol 2000;131:740-4
   PubMed Web of Science ®Google Scholar
• Song W, Furman BL, Parratt JR. Delayed protection against ischaemia-induced ventricular arrhythmias and infarct size limitation by the prior administration of Escherichia coli endotoxin. Br J Pharmacol 1996;118:2157-63
   PubMed Web of Science ®Google Scholar
• Zacharowski K, Frank S, Otto M, Lipoteichoic acid induces delayed protection in the rat heart: a comparison with endotoxin. Arterioscler Thromb Vasc Biol 2000;20:1521-8
   PubMed Web of Science ®Google Scholar
• Zhu X, Zhao H, Graveline AR, MyD88 and NOS2 are essential for toll-like receptor 4-mediated survival effect in cardiomyocytes. Am J Physiol Heart Circ Physiol 2006;291:H1900-9
   Web of Science ®Google Scholar
• Mersmann J, Berkels R, Zacharowski P, Preconditioning by toll-like receptor 2 agonist Pam3CSK4 reduces CXCL1-dependent leukocyte recruitment in murine myocardial ischemia/reperfusion injury. Crit Care Med 2010;38:903-9
   PubMed Web of Science ®Google Scholar
• Chong AJ, Shimamoto A, Hampton CR, Toll-like receptor 4 mediates ischemia/reperfusion injury of the heart. J Thorac Cardiovasc Surg 2004;128:170-9
   PubMed Web of Science ®Google Scholar
• Oyama J, Blais C Jr, Liu X, Reduced myocardial ischemia-reperfusion injury in toll-like receptor 4-deficient mice. Circulation 2004;109:784-9
   PubMed Web of Science ®Google Scholar
• Hua F, Ha T, Ma J, Protection against myocardial ischemia/reperfusion injury in TLR4-deficient mice is mediated through a phosphoinositide 3-kinase-dependent mechanism. J Immunol 2007;178:7317-24
   PubMed Web of Science ®Google Scholar
• Ao L, Zou N, Cleveland JC Jr, Myocardial TLR4 is a determinant of neutrophil infiltration after global myocardial ischemia: mediating KC and MCP-1 expression induced by extracellular HSC70. Am J Physiol Heart Circ Physiol 2009;297:H21-8
   Web of Science ®Google Scholar
• Sakata Y, Dong JW, Vallejo JG, Toll-like receptor 2 modulates left ventricular function following ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 2007;292:H503-9
   PubMed Web of Science ®Google Scholar
• Favre J, Musette P, Douin-Echinard V, Toll-like receptors 2-deficient mice are protected against postischemic coronary endothelial dysfunction. Arterioscler Thromb Vasc Biol 2007;27:1064-71
   PubMed Web of Science ®Google Scholar
• Hua F, Ha T, Ma J, Blocking the MyD88-dependent pathway protects the myocardium from ischemia/reperfusion injury in rat hearts. Biochem Biophys Res Commun 2005;338:1118-25
   PubMed Web of Science ®Google Scholar
• Hall G, Hasday JD, Rogers TB. Regulating the regulator: NF-kappaB signaling in heart. J Mol Cell Cardiol 2006;41:580-91
   PubMed Web of Science ®Google Scholar
• Morgan EN, Boyle EM Jr, Yun W, An essential role for NF-kappaB in the cardioadaptive response to ischemia. Ann Thorac Surg 1999;68:377-82
   PubMed Web of Science ®Google Scholar
• Chandrasekar B, Freeman GL. Induction of nuclear factor kappaB and activation protein 1 in postischemic myocardium. FEBS Lett 1997;401:30-4
   PubMed Web of Science ®Google Scholar
• Morishita R, Sugimoto T, Aoki M, In vivo transfection of cis element “decoy” against nuclear factor-kappaB binding site prevents myocardial infarction. Nat Med 1997;3:894-9
   PubMed Web of Science ®Google Scholar
• Brown M, McGuinness M, Wright T, Cardiac-specific blockade of NF-kappaB in cardiac pathophysiology: differences between acute and chronic stimuli in vivo. Am J Physiol Heart Circ Physiol 2005;289:H466-76
   Web of Science ®Google Scholar
• Onai Y, Suzuki J, Kakuta T, Inhibition of IκB phosphorylation in cardiomyocytes attenuates myocardial ischemia/reperfusion injury. Cardiovasc Res 2004;63:51-9
   PubMed Web of Science ®Google Scholar
• Frantz S, Tillmanns J, Kuhlencordt PJ, Tissue-specific effects of the nuclear factor kappaB subunit p50 on myocardial ischemia-reperfusion injury. Am J Pathol 2007;171:507-12
   PubMed Web of Science ®Google Scholar
• Romson JL, Hook BG, Kunkel SL, Reduction of the extent of ischemic myocardial injury by neutrophil depletion in the dog. Circulation 1983;67:1016-23
   PubMed Web of Science ®Google Scholar
• Engler RL, Dahlgren MD, Morris DD, Role of leukocytes in response to acute myocardial ischemia and reflow in dogs. Am J Physiol 1986;251:H314-23
   PubMed Web of Science ®Google Scholar
• Maroko PR, Carpenter CB, Chiariello M, Reduction by cobra venom factor of myocardial necrosis after coronary artery occlusion. J Clin Invest 1978;61:661-70
   PubMed Web of Science ®Google Scholar
• Hwang MW, Matsumori A, Furukawa Y, Neutralization of interleukin-1beta in the acute phase of myocardial infarction promotes the progression of left ventricular remodeling. J Am Coll Cardiol 2001;38:1546-53
   PubMed Web of Science ®Google Scholar
• Takashi E, Ashraf M. Pathologic assessment of myocardial cell necrosis and apoptosis after ischemia and reperfusion with molecular and morphological markers. J Mol Cell Cardiol 2000;32:209-24
   PubMed Web of Science ®Google Scholar
• Freude B, Masters TN, Robicsek F, Apoptosis is initiated by myocardial ischemia and executed during reperfusion. J Mol Cell Cardiol 2000;32:197-208
   PubMed Web of Science ®Google Scholar
• Choi KB, Wong F, Harlan JM, Lipopolysaccharide mediates endothelial apoptosis by a FADD-dependent pathway. J Biol Chem 1998;273:20185-8
   PubMed Web of Science ®Google Scholar
• Chao W, Shen Y, Zhu X, Lipopolysaccharide improves cardiomyocyte survival and function after serum deprivation. J Biol Chem 2005;280:21997-2005
   PubMed Web of Science ®Google Scholar
• Aliprantis AO, Yang RB, Mark MR, Cell activation and apoptosis by bacterial lipoproteins through toll-like receptor-2. Science 1999;285:736-9
   PubMed Web of Science ®Google Scholar
• Aliprantis AO, Yang RB, Weiss DS, The apoptotic signaling pathway activated by Toll-like receptor-2. EMBO J 2000;19:3325-36
   PubMed Web of Science ®Google Scholar
• Frantz S, Kelly RA, Bourcier T. Role of TLR2 in the activation of nuclear factor kappaB by oxidative stress in cardiac myocytes. J Biol Chem 2001;276:5197-203
   PubMed Web of Science ®Google Scholar
• Dong JW, Vallejo JG, Tzeng HP, Innate immunity mediates myocardial preconditioning through Toll-like receptor 2 and TIRAP-dependent signaling pathways. Am J Physiol Heart Circ Physiol 2010;298:H1079-87
   PubMed Web of Science ®Google Scholar
• Thomas JA, Haudek SB, Koroglu T, IRAK1 deletion disrupts cardiac Toll/IL-1 signaling and protects against contractile dysfunction. Am J Physiol Heart Circ Physiol 2003;285:H597-606
   PubMed Web of Science ®Google Scholar
• Nemoto S, Vallejo JG, Knuefermann P, Escherichia coli LPS-induced LV dysfunction: role of toll-like receptor-4 in the adult heart. Am J Physiol Heart Circ Physiol 2002;282:H2316-23
   PubMed Web of Science ®Google Scholar
• Tavener SA, Long EM, Robbins SM, Immune cell Toll-like receptor 4 is required for cardiac myocyte impairment during endotoxemia. Circ Res 2004;95:700-7
   Google Scholar
• Tidswell M, Tillis W, Larosa SP, Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis. Crit Care Med 2010;38:72-83
   PubMed Web of Science ®Google Scholar
• Knuefermann P, Sakata Y, Baker JS, Toll-like receptor 2 mediates Staphylococcus aureus-induced myocardial dysfunction and cytokine production in the heart. Circulation 2004;110:3693-8
   PubMed Web of Science ®Google Scholar
• Zou L, Feng Y, Chen YJ, Toll-like receptor 2 plays a critical role in cardiac dysfunction during polymicrobial sepsis. Crit Care Med 2010;38:1335-42
   PubMed Web of Science ®Google Scholar
• Knuefermann P, Schwederski M, Velten M, Bacterial DNA induces myocardial inflammation and reduces cardiomyocyte contractility: role of toll-like receptor 9. Cardiovasc Res 2008;78:26-35
   PubMed Web of Science ®Google Scholar
• Satoh M, Shimoda Y, Maesawa C, Activated toll-like receptor 4 in monocytes is associated with heart failure after acute myocardial infarction. Int J Cardiol 2006;109:226-34
   PubMed Web of Science ®Google Scholar
• Frantz S, Fraccarollo D, Wagner H, Sustained activation of nuclear factor kappa B and activator protein 1 in chronic heart failure. Cardiovasc Res 2003;57:749-56
   PubMed Web of Science ®Google Scholar
• Frantz S, Stoerk S, Ok S, Effect of chronic heart failure on nuclear factor kappa B in peripheral leukocytes. Am J Cardiol 2004;94:671-3
   PubMed Web of Science ®Google Scholar
• Tillmanns J, Carlsen H, Blomhoff R, Caught in the act: in vivo molecular imaging of the transcription factor NF-kappaB after myocardial infarction. Biochem Biophys Res Commun 2006;342:773-4
   PubMed Web of Science ®Google Scholar
• Shishido T, Nozaki N, Yamaguchi S, Toll-like receptor-2 modulates ventricular remodeling after myocardial infarction. Circulation 2003;108:2905-10
   PubMed Web of Science ®Google Scholar
• Mersmann J, Habeck K, Latsch K, Left ventricular dilation in toll-like receptor 2 deficient mice after myocardial ischemia/reperfusion through defective scar formation. Basic Res Cardiol 2011;106:89-98
   PubMed Web of Science ®Google Scholar
• Riad A, Jager S, Sobirey M, Toll-like receptor-4 modulates survival by induction of left ventricular remodeling after myocardial infarction in mice. J Immunol 2008;180:6954-61
   PubMed Web of Science ®Google Scholar
• Timmers L, Sluijter JP, van Keulen JK, Toll-like receptor 4 mediates maladaptive left ventricular remodeling and impairs cardiac function after myocardial infarction. Circ Res 2008;102:257-64
   PubMed Web of Science ®Google Scholar
• Frantz S, Hu K, Bayer B, Absence of NF-kappaB subunit p50 improves heart failure after myocardial infarction. FASEB J 2006;20:1918-20
   PubMed Web of Science ®Google Scholar
• Van Tassell BW, Seropian IM, Toldo S, Pharmacologic inhibition of myeloid differentiation factor 88 (MyD88) prevents left ventricular dilation and hypertrophy after experimental acute myocardial infarction in the mouse. J Cardiovasc Pharmacol 2010;55:385-90
   PubMed Web of Science ®Google Scholar
• Timmers L, van Keulen JK, Hoefer IE, Targeted deletion of nuclear factor kappaB p50 enhances cardiac remodeling and dysfunction following myocardial infarction. Circ Res 2009;104:699-706
   PubMed Web of Science ®Google Scholar
• Kawano S, Kubota T, Monden Y, Blockade of NF-kappaB ameliorates myocardial hypertrophy in response to chronic infusion of angiotensin II. Cardiovasc Res 2005;67:689-98
   PubMed Web of Science ®Google Scholar
• Kawano S, Kubota T, Monden Y, Blockade of NF-kappaB improves cardiac function and survival after myocardial infarction. Am J Physiol Heart Circ Physiol 2006;291:H1337-44
   PubMed Web of Science ®Google Scholar
• Frantz S, Bauersachs J. Regarding the article by Timmers, et al. Circ Res 2009;104:e60; author reply e1
   PubMed Web of Science ®Google Scholar
• Ha T, Li Y, Hua F, Reduced cardiac hypertrophy in toll-like receptor 4-deficient mice following pressure overload. Cardiovasc Res 2005;68:224-34
   PubMed Web of Science ®Google Scholar
• Zhang D, Gaussin V, Taffet GE, TAK1 is activated in the myocardium after pressure overload and is sufficient to provoke heart failure in transgenic mice. Nat Med 2000;6:556-63
   PubMed Web of Science ®Google Scholar
• Ha T, Hua F, Li Y, Blockade of MyD88 attenuates cardiac hypertrophy and decreases cardiac myocyte apoptosis in pressure overload-induced cardiac hypertrophy in vivo. Am J Physiol Heart Circ Physiol 2006;290:H985-94
   Web of Science ®Google Scholar
• Kratsios P, Huth M, Temmerman L, Antioxidant amelioration of dilated cardiomyopathy caused by conditional deletion of NEMO/IKKgamma in cardiomyocytes. Circ Res 2010;106:133-44
   PubMed Web of Science ®Google Scholar
• Freund C, Schmidt-Ullrich R, Baurand A, Requirement of nuclear factor-kappaB in angiotensin II- and isoproterenol-induced cardiac hypertrophy in vivo. Circulation 2005;111:2319-25
   PubMed Web of Science ®Google Scholar
• Riad A, Bien S, Gratz M, Toll-like receptor-4 deficiency attenuates doxorubicin-induced cardiomyopathy in mice. Eur J Heart Fail 2008;10:233-43
   PubMed Web of Science ®Google Scholar
• Nozaki N, Shishido T, Takeishi Y, Modulation of doxorubicin-induced cardiac dysfunction in toll-like receptor-2-knockout mice. Circulation 2004;110:2869-74
   PubMed Web of Science ®Google Scholar
• Kast RE, Foley KF, Focosi D. Doxorubicin cardiomyopathy via TLR2 stimulation: potential for prevention using current anti-retroviral inhibitors such as ritonavir and nelfinavir. Hematol Oncol 2007;25:96-7
   PubMed Web of Science ®Google Scholar
• Hill SL, Rose NR. The transition from viral to autoimmune myocarditis. Autoimmunity 2001;34:169-76
   PubMed Web of Science ®Google Scholar
• Zimmermann O, Kochs M, Zwaka TP, Myocardial biopsy based classification and treatment in patients with dilated cardiomyopathy. Int J Cardiol 2005;104:92-100
   PubMed Web of Science ®Google Scholar
• Negishi H, Osawa T, Ogami K, A critical link between Toll-like receptor 3 and type II interferon signaling pathways in antiviral innate immunity. Proc Natl Acad Sci USA 2008;105:20446-51
   PubMed Web of Science ®Google Scholar
• Richer MJ, Lavallee DJ, Shanina I, Toll-like receptor 3 signaling on macrophages is required for survival following coxsackievirus B4 infection. PLoS One 2009;4:e4127
   PubMed Web of Science ®Google Scholar
• Hardarson HS, Baker JS, Yang Z, Toll-like receptor 3 is an essential component of the innate stress response in virus-induced cardiac injury. Am J Physiol Heart Circ Physiol 2007;292:H251-8
   PubMed Web of Science ®Google Scholar
• Gorbea C, Makar KA, Pauschinger M, A role for Toll-like receptor 3 variants in host susceptibility to enteroviral myocarditis and dilated cardiomyopathy. J Biol Chem 2010;285:23208-23
   PubMed Web of Science ®Google Scholar
• Fairweather D, Yusung S, Frisancho S, IL-12 receptor beta1 and Toll-like receptor 4 increase IL-1beta- and IL-18-associated myocarditis and coxsackievirus replication. J Immunol 2003;170:4731-7
   PubMed Web of Science ®Google Scholar
• Satoh M, Nakamura M, Akatsu T, Expression of Toll-like receptor 4 is associated with enteroviral replication in human myocarditis. Clin Sci (Lond) 2003;104:577-84
   PubMed Web of Science ®Google Scholar
• Fuse K, Chan G, Liu Y, Myeloid differentiation factor-88 plays a crucial role in the pathogenesis of Coxsackievirus B3-induced myocarditis and influences type I interferon production. Circulation 2005;112:2276-85
   PubMed Web of Science ®Google Scholar
• Riad A, Westermann D, Zietsch C, TRIF is a critical survival factor in viral cardiomyopathy. J Immunol 2011;186:2561-70
   PubMed Web of Science ®Google Scholar
• Triantafilou K, Orthopoulos G, Vakakis E, Human cardiac inflammatory responses triggered by Coxsackie B viruses are mainly Toll-like receptor (TLR) 8-dependent. Cell Microbiol 2005;7:1117-26
   PubMed Web of Science ®Google Scholar
• Gonnella PA, Waldner H, Del Nido PJ, Inhibition of experimental autoimmune myocarditis: peripheral deletion of TcR Vbeta 8.1, 8.2+ CD4+ T cells in TLR4 deficient mice. J Autoimmun 2008;31:180-7
   PubMed Web of Science ®Google Scholar
• Marty RR, Dirnhofer S, Mauermann N, MyD88 signaling controls autoimmune myocarditis induction. Circulation 2006;113:258-65
   PubMed Web of Science ®Google Scholar
• Pagni PP, Traub S, Demaria O, Contribution of TLR7 and TLR9 signaling to the susceptibility of MyD88-deficient mice to myocarditis. Autoimmunity 2010;43:275-87
   PubMed Web of Science ®Google Scholar
• Andreakos E, Sacre S, Foxwell BM, The toll-like receptor-nuclear factor kappaB pathway in rheumatoid arthritis. Front Biosci 2005;10:2478-88
   PubMed Web of Science ®Google Scholar
• Schroder NW, Arditi M. The role of innate immunity in the pathogenesis of asthma: evidence for the involvement of Toll-like receptor signaling. J Endotoxin Res 2007;13:305-12
   PubMedGoogle Scholar
• Huang Q, Pope RM. Toll-like receptor signaling: a potential link among rheumatoid arthritis, systemic lupus, and atherosclerosis. J Leukoc Biol 2010;88:253-62
   PubMed Web of Science ®Google Scholar
• Ulevitch RJ. Therapeutics targeting the innate immune system. Nat Rev Immunol 2004;4:512-20
   PubMed Web of Science ®Google Scholar
• Rice TW, Wheeler AP, Bernard GR, A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis. Crit Care Med 2010;38:1685-94
   PubMed Web of Science ®Google Scholar
• Makkouk A, Abdelnoor AM. The potential use of Toll-like receptor (TLR) agonists and antagonists as prophylactic and/or therapeutic agents. Immunopharmacol Immunotoxicol 2009;31:331-8
   PubMed Web of Science ®Google Scholar
• Methe H, Kim JO, Kofler S, Statins decrease Toll-like receptor 4 expression and downstream signaling in human CD14+ monocytes. Arterioscler Thromb Vasc Biol 2005;25:1439-45
   PubMed Web of Science ®Google Scholar
• Vanags D, Williams B, Johnson B, Therapeutic efficacy and safety of chaperonin 10 in patients with rheumatoid arthritis: a double-blind randomised trial. Lancet 2006;368:855-63
   PubMed Web of Science ®Google Scholar
• Anker SD, Coats AJ. How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol 2002;86:123-30
   PubMed Web of Science ®Google Scholar